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Abstract 
A model-based insulin sensitivity parameter (SI) is often used in glucose-insulin 
system models to define the glycaemic response to insulin. As a parameter 
identified from clinical data, insulin sensitivity can be affected by blood glucose 
(BG) sensor error and measurement timing error, which can subsequently 
impact analyses or glycaemic variability during control. This study assessed the 
impact of both measurement timing and BG sensor errors on identified values of 
SI and its hour-to-hour variability within a common type of glucose-insulin 
system model. 
Retrospective clinical data were used from 270 patients admitted to the 
Christchurch Hospital ICU between 2005 and 2007 to identify insulin sensitivity 
profiles. We developed error models for the Abbott Optium Xceed glucometer 
and measurment timing from clinical data. The effect of these errors on the re-
identified insulin sensitivity was investigated by Monte-Carlo analysis. 
The results of the study show that timing errors in isolation have little clinically 
significant impact on identified SI level or variability. The clinical impact of 
changes to SI level induced by combined sensor and timing errors is likely to be 
significant during glycaemic control. Identified values of SI were mostly (90th 
percentile) within 29% of the true value when influenced by both sources of 
error. However, these effects may be overshadowed by physiological factors 
arising from the critical condition of the patients or other under-modelled or un-
modelled dynamics. Thus, glycaemic control protocols that are designed to work 
with data from glucometers need to be robust to these errors and not be too 
aggressive in dosing insulin.  
 
1 Introduction 
Physiological glucose-insulin system models typically rely on some form of 
insulin sensitivity parameter to characterise the patient-specific glycaemic 
response to exogenous insulin [1, 2]. This model-based insulin sensitivity 
parameter (SI) is identified for some period of time using blood glucose (BG) 
concentration and insulin and nutrition administration data. Errors in blood 
glucose concentration and measurement timing can thus affect the identified 
values of SI. 
In the busy intensive care unit (ICU) environment, BG measurements are rarely 
taken and recorded at an exact, scheduled time. Sensor errors add uncertainty to 
the measured BG concentration. Both errors propagate through to SI during 
parameter identification, which in turn may impact subsequent analyses or 
glycaemic variability during control. 
Typical point-of-care glucometers claim to have measurement errors in the 
range 2-10% [3-7]. The uncertainty in BG concentration resulting from sensor 
error impacts the identified values of SI through altering the glucose flux that 
must be balanced by the insulin-mediated glucose disposal term in the glucose-
insulin system model. 
The objective of this investigation was to assess the impact of both measurement 
timing and sensor errors on identified values of SI and its hour-to-hour 
variability. Specifically, the SI parameter from a glucose-insulin system model 
similar to that described by Lin et al. [1] was investigated with patient data from 
the Christchurch Hospital ICU. 
 
2 Subjects and Methods 
2.1 Patients 
This study was conducted as retrospective analyses of data from 270 patients 
admitted to the Christchurch Hospital ICU between 2005 and 2007. All patients 
were on the SPRINT protocol for at least 24 hours [8]. Table 1 shows a summary 
of the cohort details. The Upper South Regional Ethics Committee, New Zealand 
granted approval for the audit, analysis and publication of this data. 
Table 1. Cohort details summary. Data are shown as median [interquartile range] where appropriate 
N 270 
Age (years) 65 [49-73] 
Gender (M/F) 165/105 
Operative/Non-Operative 104/166 
Hospital mortality (%) 27% 
APACHE II score 19 [16-25] 
APACHE II ROD (%) 30 [17-53] 
Diabetic status (T1DM/T2DM) 10/34 
ICU length of stay (hrs) 160 [77-346] 
 
2.2 Model-based insulin sensitivity 
The glucose-insulin system model used in this study was an enhanced version of 
the ICING model described by Lin et al. [1], with a new endogenous insulin 
secretion sub-model (7) derived from data not yet published. The model is 
defined below in Equations (1)-(7). Model parameters, rates and constants were 
generally as described in Lin et al. [1], except for nI, nC  and VI which have been 
adjusted to 0.006 min-1, 0.006 min-1 and 4.0 L, respectively. These changes were 
made based on an analysis of results from several microdialysis studies and the 
population parameters from Van Cauter et al. [9]. 
Endogenous insulin secretion was modelled as a function of BG. Sub-model 
parameters, umin and umax are 16.7 mU.min-1 and 266.7 mU.min-1, respectively. 
For non-diabetic patients, k1and k2 take the values 14.9 mU.L.mmol-1.min-1 and -
49.9 mU.min-1. 
The model was implemented in MATLAB (2012a, Natick, MA), and a value of SI 
identified each hour for every patient using clinical BG, insulin and nutrition 
records. The parameter identification was performed using an integral method 
that ensured the global optimum value was located [10].  
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The model-based insulin sensitivity parameter has been shown to correlate well 
with the insulin sensitivity index (ISI) determined by the gold-standard 
euglycaemic-hyperinsulinaemic clamp (r >0.90) [11]. Hour-to-hour SI variability 
is defined in (8). 





2.3 Blood glucose sensor error 
This study uses preliminary information from an on-going investigation 
evaluating the performance of several different point-of-care glucometers in the 
Christchurch Hospital ICU. For the purposes of this study, an error model was 
derived for the Abbott Optium Xceed glucometer (Abbott Diabetes Care, 
Alameda, CA), a commonly available, inexpensive device that measures the 
glucose concentration in a whole blood sample, and reports a plasma equivalent 
glucose concentration. Test strips used in this study were validated for a 
haematocrit range of 20-70% [12]. 
The study in Christchurch used arterial blood samples, each drawn by an 
experience intensive care nurse. The glucose concentration of each sample was 
determined using a Radiometer ABL90 Flex blood gas analyser (BGA) 
(Copenhagen, Denmark) and simultaneously with up to 5 separate glucometers. 
However, due to device error, availability, or clinical reasons, some samples 
were tested on fewer than 5 glucometers. All measurements were completed 
within 5 minutes of the blood draw. Data from 242 samples (758 glucometer 
measurements) were available to derive the error model from 758 paired 
measurements.  
Whole blood glucose results from the BGA were adjusted with the measured 
haematocrit [13] to yield plasma glucose concentrations for direct comparison 
with the glucometers. Figure 1 shows scatter and Bland-Altman plots of the 
paired data and Figure 2 shows the kernel density model of the glucometer BG 
values given the BGA values.  
 
Figure 1. Scatter (left) and Bland-Altman (right) plots of Abbott Optium Xceed glucometer 




Figure 2. Kernel density model of Abbott Optium Xceed glucometer performance based on 758 paired 
measurments with a blood gas analyser (BGA) 
 
Table 2 shows a simplified, binned error model derived from the paired data, for 
comparison with the published errors (from test-strip packet insert) presented 
in Table 3 [12]. An estimate of the sensor bias was derived from the correlation 
data. Precision was modelled using the reported standard deviations, linearly 
interpolated within the reported range and held constant outside.  
Table 2. Binned errors for the Abbott Optium Xceed glucometer based on paired measurements from 
Christchurch Hospital ICU. 
Reference BG 
(mmol/L) 
< 5.9 6.0 - 6.9 7.0 – 7.9 8.0 – 8.9 > 9.0 
Number of 
measurements 
88 180 261 156 73 
Error mean 
(mmol/L) 
0.28 0.19 -0.05 -0.56 -0.26 
Error std. dev. 
(mmol/L) 











< 2.4 2.4 5.6 8.0 20 > 20 
Error mean 
(mmol/L) 
+0.25 +0.25 +0.19 +0.14 -0.10 -0.10 
Error std. dev. 
(mmol/L) 
0.13 0.13 0.22 0.30 0.94 0.94 
 
2.4 Timing error 
Measurements and interventions during the SPRINT protocol were 1 or 2-hourly 
and intended to be taken on the hour. These measurements were recorded by 
hand and attributed to the nearest hour on the standard paper 24-hour charts 
used in the Christchurch Hospital ICU. Hence, any discrepancies between the 
actual measurement time and the ‘nearest hour’ were lost. 
Recent pilot trials of the STAR (Stochastic TARgeted) protocol at Christchurch 
Hospital ICU [14] provide data to generate a timing error model (1651 
measurements on 20 patients). The STAR protocol is implemented on a tablet 
computer, thus the exact time when BG measurements were entered was 
recorded and can be compared to the written records. Using the discrepancies 
between scheduled and actual BG measurements, a model of timing error can be 
generated and applied to data from the SPRINT protocol. Although the STAR 
protocol differs from SPRINT, particularly with its computerised interface, it was 
used by the same clinical staff in the same unit. Hence, it may be assumed that 
timing errors in making measurements will be similar. 
Timing errors were limited to a maximum of 28 minutes for this analysis.  Errors 
of ±30 minutes or more are considered as missed or additional treatments as 
they are closer to the next hour than the previous. Both these cases relate to 
protocol compliance and are thus are not considered as timing errors for the 
purposes of this analysis. 92% of recorded timing errors fell within the range -28 
to 28 minutes. 
The empirical timing error distributions are shown in Figure 3. Errors from 
these distributions were applied additively to the SPRINT data by randomly 
sampling from the error vectors. The errors were applied to both the 
measurement and intervention timing. Thus, the measurements and 
interventions remained synchronised, as they would in the hospital.  
 
Figure 3. Timing error models based on data from the STAR pilot trials [14]. Errors from 1- and 2 hour 
measurements are shown on the left and right, respectively. 
 
2.5 Analysis 
To assess the effects of random timing and sensor errors on SI, Monte Carlo 
simulations were performed.  Due to the non-linearity of the model equations 
and the numerical identification of SI, an analytical derivation of these effects 
was not possible. 
For the Monte Carlo simulations, the SI profile of each patient in the cohort was 
refitted n = 50 times with randomly sampled errors from applied to the observed 
timing and BG concentrations. The SI profiles identified without additional 
random errors were considered the ‘true’ profiles, and the Monte Carlo profiles 
were compared to these to assess the impact each of the sources of error. 
Comparisons of both SI level and hour-to-hour variability were made. 
BG errors were sampled from the kernel density model, within the range 4.4-
11.9 mmol/L in which paired data existed. Outside this range, errors were 
assumed to be normally distributed with parameters shown in Table 3, from the 
published error model. 
To facilitate comparisons when timing errors were applied, SI was identified in 
60-minute intervals, rather than between BG measurements. This use of fixed, 
60-minute fitting intervals and linear interpolation between measurements is 
consistent with the methodology used for glycaemic control by the STAR 
protocol. 
To analyse the impact of errors on the identified SI level, the variation induced 
by the simulated errors at each hour was assessed across the Monte Carlo 
simulations. Figure 3 illustrates the methodology for SI level comparisons 
between the n Monte Carlo simulations and the true data. 
 
Figure 4. SI level comparison method for the Monte Carlo simulations with added sensor and timing 
error. The width of the interquartile range of differences was used to characterise the variability in level 
induced by the errors. 
This analysis method results in one interquartile range (IQR) width value per 
patient hour. For the 270 patient SPRINT cohort, there were approximately 
43,000 hours of data. These 43,000 IQR widths were presented as cumulative 
distributions to show the overall effect of the errors on the cohort. 
The hour-to-hour variability (%) of simulated data could not be compared to the 
true variability using ratios as the distribution of true variability was centred 


















hour-to-hour variability can be quantified by the width of the IQR across the 
simulations at each hour.
3 Results and Discussion 
3.1 Timing error 
Figure 5 shows the impact of timing errors on identified SI level (left panel) and 
variability (right panel). For 90% of hours, the IQR width of SI level was 10%. 
Thus, for those 38,700 hours, half the simulations resulted in SI values within 
±5% of the true value, in the case of a symmetrical distribution. Similarly, for 
variability, 90% of hours had an IQR width of hour-to-hour changes of less than 
14%, or ±7% about the simulation median.  
 
Figure 5. The impact of timing error on SI level (left panel) and hour-to-hour variability (right panel), 
determined by Monte Carlo simulation. 
These results show that typical timing errors in isolation have a relatively small 
impact on the level and variability of SI. With a median absolute difference 
between the simulated and actual measurement intervals of 9 minutes and using 
bolus insulin delivery, this result is not too surprising. Unlike infused insulin, 
bolus delivery ensures that the entire prescribed dose is always administered, 
regardless of the time between measurements. In addition, timing discrepancies 
only affect the later parts of the interstitial insulin profile, where concentrations 
are lowest and thus contribute least to the area under the curve used in fitting 
the SI parameter [10]. 
3.2 Blood glucose sensor error 
Figure 6 shows the impact of BG sensor errors on SI level (left panel) and 
variability (right panel). Results from both error models are presented, with the 
solid lines indicating the model derived from clinical paired measurements 
(Figure 2) and the dashed line indicating the model derived from published data 
(Table 3). For 90% of hours, the IQR widths of SI level were less than 65% and 
23% for the clinical and published models, respectively. Thus, for those 38,700 
hours, half the simulations resulted in SI values within approximately ±33% and 
±12% of the true value, in the case of a symmetrical distribution. Similarly, for 
variability, 90% of hours had IQR widths of hour-to-hour changes of less than 
112% and 38%, or ±56% and ±19% about the simulation median. 
The variability induced in both SI level and variability is significantly greater 
than that due to timing error in both cases. Additionally, the error model derived 
from clinical measurements causes greater variability than that from the 
published data.  
 
Figure 6. The impact of BG sensor error on SI level (left panel) and hour-to-hour variability (right 
panel), determined by Monte Carlo simulation.  
3.3 Combined measurement error 
Figure 7 shows the impact of the combined timing and BG sensor errors on SI 
level (left panel) and variability (right panel). The previous two sections have 
characterised the individual contributions of timing and sensor error. This 
analysis combines them, simulating errors seen in the real, clinical situation. The 
error model derived from paired clinical data was used as it represents the 
performance of the glucometer in an actual critical care environment. 
For 90% of hours, the IQR width of SI level was less than 58%. Thus, assuming a 
symmetrical distribution, half the simulations resulted in SI values within 
approximately ±29% of the true value for these 38,700 hours. Similarly for 
variability, the 90th percentile was 93%, indicating that for half the simulations 
the hour-to-hour variability of SI was within ±47%. 
 
Figure 7. The impact of combined timing and BG sensor error on SI level (left panel) and hour-to-hour 
variability (right panel), determined by Monte Carlo simulation. The results of Figure 5 (paired 
measurement model) are shown as grey lines for comparison. 
The results from Figure 6 are also shown on Figure 7 as grey lines. It is obvious 
that the two error sources are not additive and that the results are very similar. 
This similarity is possibly due to the effects of the two separate error sources 
cancelling each other out. 
3.4 Discussion 
The clinical impact during glycaemic control of changes to SI level induced by 
sensor and timing errors is potentially quite significant. Identified values of SI 
were mostly within 29% of the true value when influenced by both sources of 
error. However, changes in SI greater than 20% were seen with glucocorticoid 
treatment [15] and improving patient condition over the first 18 hours of ICU 
stay [16]. Thus, glycaemic control protocols that are designed to work with data 
from glucometers need to be robust to these errors and not be too aggressive in 
dosing insulin.  
A second, potentially clinically significant, impact is on analytical use of SI as a 
marker of injury or change in state. This analysis shows that identified short-
term changes in SI could be a result of measurement timing or sensor errors, 
rather than true physiological phenomena. Hence, using changes in SI level as a 
diagnostic must be done with caution, potentially looking at longer-term trends, 
where the effects of random errors may be cancelled by averaging over time. 
In the context of the STAR protocol, the additional hour-to-hour variability 
caused by sensor and timing errors may be clinically significant. STAR uses a 
stochastic model of expected SI hour-to-hour variability to forecast the results of 
potential interventions and avoid hypoglycaemia. The stochastic model is 
derived from historical data measured with glucometers (Arkray 
SuperGlucocard II, Arkray Inc. Japan) and whole blood, and therefore includes 
the effects of BG sensor error that are likely to be of a similar magnitude to those 
observed in this study [4]. Specifically, the relatively large, ±47%, range of hour-
to-hour variability about the median caused by errors, suggests that a significant 
proportion of the expected variability may be a result these errors, rather than 
explicit physiological variability.  
It is interesting to note that combining timing and sensor errors results in 
slightly less variability than the sensor error alone (Figure 7). This is likely a 
result of the effects of the two error sources cancelling each other out.   
3.5 Potential for reducing error and its impact on glycaemic control 
There is no effective way to remove these errors as they are random and apply 
equally to all patients. The only available option is to reduce the magnitude of 
the errors where possible and carefully manage their impact. The timing error 
distribution in Figure 3 shows that more than 85% of measurements are within 
10 minutes of the scheduled time, which is a very good result in a busy ICU 
environment.  
In contrast, BG sensor errors can be reduced with better, more accurate, but 
likely more expensive equipment (for example, Abbott i-STAT, Nova StatStrip 
Glucose or a blood gas analyser). The Christchurch ICU is currently investigating 
several point-of-care blood glucose measurement devices for future clinical use. 
However, all measurement devices have some degree of uncertainty. In addition, 
other factors such as interfering substances and sampling procedure can also 
have a large impact on the accuracy of a measurement [17, 18]. Thus, glucose 
control protocols must be robust to the impact of these errors. 
The STAR protocol manages the variability induced in SI by considering the 
extreme percentiles of the stochastic model. By selecting interventions so that 
the forecast probability of the next blood glucose measurement being above or 
below the target band is just 5% for each case, most of the induced variability is 
contained within the band, thus mitigating the clinical impact and potential risk 
of hypoglycaemia. 
It is interesting to note the differences in accuracy of the glucometer between the 
published data and that obtained in a real, clinical setting. This study used data 
obtained from arterial blood samples collected by trained clinical staff and 
measured within 5 minutes, minimising the potential for additional error 
through device misuse [17, 18]. However, there were still appreciable 
differences, and these may increase further in normal use, when clinical staff are 
not focused on a study protocol that is explicitly designed to reduce errors. 
 
4 Conclusions 
The objective of this study was to assess and quantify the impact of typical 
timing and BG sensor errors on the level and variability of model-based SI. 
Specifically, the variability of level and the variability of SI hour-to-hour 
variability were investigated under the influence of these sources of error, both 
separately and combined. Measurement timing errors were shown to have a 
significant influence on the identified value of the SI parameter. The BG 
concentration errors of the Abbott Optium Xceed glucometer had a larger effect 
on SI and dominated the combined analysis. 
The clinical impact of errors on SI level during glycaemic control is likely to be 
significant and possibly detrimental to control performance. However, these 
changes are of similar magnitude to changes from physiological or therapy 
factors arising from the critical condition of the patients, which are already dealt 
with by control protocols. Thus, glycaemic control protocols that are designed to 
work with data from glucometers need to be robust to these errors and not be 
too aggressive in dosing insulin. In contrast, the impact of errors on hour-to-hour 
SI variability is more pronounced and may impact the way the SI parameter is 
utilised for control and analysis. 
This analysis indicated that for a given SI level, variability induced by errors 
might dominate the IQR of the probability density function describing SI for the 
subsequent hour. In addition, using changes in SI level as a diagnostic must be 
done with caution, potentially looking at longer-term trends, where the effects of 
random errors may be cancelled by averaging over time. 
Given the random nature of these errors, the only feasible method of mitigation 
is to use more accurate BG sensors and glycaemic control protocols that are 
robust to the impact of the errors. Understanding the effect of sensor and timing 
errors on SI allows their impact to be taken into account when using the 
parameter for control and analysis. 
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